Wang X, Cicuttini F, Jin X, Wluka A E, Han W, Zhu Z, Blizzard L, Antony B, Winzenberg T, Jones G, Ding C
Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Osteoarthritis Cartilage. 2017 Aug;25(8):1304-1312. doi: 10.1016/j.joca.2017.02.804. Epub 2017 Mar 6.
To develop a measure of knee joint effusion-synovitis volume and to examine the effect of vitamin D supplementation on effusion-synovitis in people with knee osteoarthritis (OA) and low vitamin D levels over 24 months.
Symptomatic knee OA patients with low 25-(OH)D levels (12.5-60 nmol/l) were recruited for a multi-centre, randomised, placebo-controlled and double-blind trial. Participants (age 63 ± 7 years, 208 females) were allocated to either 50,000 IU monthly vitamin D (n = 209) or placebo (n = 204) for 24 months. Knee effusion-synovitis volume in suprapatellar and other regions was measured on magnetic resonance imaging (MRI) using OsiriX software. The intra-class correlation coefficients (ICCs) were used to test inter- and intra-rater reliabilities. The least significant change criterion was used to define the increase/decrease in effusion-synovitis volume.
The reproducibilities of effusion-synovitis volume measurement were high with ICCs ranging from 0.93 to 0.99. Over 24 months, effusion-synovitis volume remained stable in the vitamin D group but increased in placebos with a significant between-group difference (-1.94 ml, 95% confidence interval (CI): -3.54, -0.33). This effect was evident in those with baseline effusion-synovitis and with suprapatellar effusion-synovitis. The proportion with an increase in effusion-synovitis volume was lower in the vitamin D group than placebo (risk ratio (RR): 0.87, 95% CI: 0.77, 0.97).
This highly reproducible effusion-synovitis volume measurement could be a promising outcome measure in OA trials. Vitamin D supplementation could retard the progression of effusion-synovitis which can potentially benefit people with an inflammatory OA phenotype.
制定一种测量膝关节积液 - 滑膜炎体积的方法,并研究补充维生素D对膝关节骨关节炎(OA)且维生素D水平低的患者在24个月内积液 - 滑膜炎的影响。
招募25 -(OH)D水平低(12.5 - 60 nmol/l)的有症状膝关节OA患者进行一项多中心、随机、安慰剂对照和双盲试验。参与者(年龄63±7岁,208名女性)被分配到每月50,000 IU维生素D组(n = 209)或安慰剂组(n = 204),为期24个月。使用OsiriX软件在磁共振成像(MRI)上测量髌上及其他区域的膝关节积液 - 滑膜炎体积。组内相关系数(ICC)用于测试评分者间和评分者内的可靠性。采用最小显著变化标准来定义积液 - 滑膜炎体积的增加/减少。
积液 - 滑膜炎体积测量的重复性很高,ICC范围为0.93至0.99。在24个月内,维生素D组的积液 - 滑膜炎体积保持稳定,而安慰剂组增加,组间差异显著(-1.94 ml,95%置信区间(CI):-3.54,-0.33)。这种效应在基线有积液 - 滑膜炎和髌上积液 - 滑膜炎的患者中明显。维生素D组积液 - 滑膜炎体积增加的比例低于安慰剂组(风险比(RR):0.87,95% CI:0.77,0.97)。
这种具有高度可重复性的积液 - 滑膜炎体积测量方法可能是OA试验中一个有前景的结局指标。补充维生素D可能会延缓积液 - 滑膜炎的进展,这可能对具有炎症性OA表型的患者有益。